All In Biotech

Drug Trial Radar · NCT04923607

Phase I Clinical Trial of TQC2731 Injection

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of TQC2731 Injection in Healthy Adult Subjects and Patients With Severe Asthma

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

96

Planned (sponsor's estimate)

Start

Jun 25, 2021

Primary completion

Aug 25, 2023

Study completion Aug 25, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.

Conditions

  • Asthma Severe Persistent Controlled

Interventions

  • TQC2731Drug

    TQC2731 injection

  • PlaceboDrug

    Matching placebo with no active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (healthy subject)Number of participants with abnormal clinical symptomsTime frame: appropriatly up to Day 253
  2. (healthy subject)Number of participants with abnormal physical examinationTime frame: appropriatly up to Day 253
  3. (healthy subject)Number of participants with abnormal vital signsTime frame: appropriatly up to Day 253
  4. (asthma subject)Number of participants with abnormal laboratory examinationsTime frame: appropriatly up to Day 253

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Zhengzhou University

    Henan, Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.